Filter
1485
Filtered Results: 1485
Text search:
vaccine
trial
Featured
Recommendations
177
New Publications
335
Language
Document type
No document type
665
Studies & Reports
281
Guidelines
254
Manuals
86
Fact sheets
72
Strategic & Response Plan
64
Situation Updates
20
Training Material
16
Resource Platforms
12
Infographics
7
Videos
5
Brochures
2
App
1
Countries / Regions
Global
72
India
43
Sierra Leone
35
Liberia
35
Kenya
34
Nigeria
29
South Africa
28
Ethiopia
24
Western and Central Europe
22
Uganda
21
West and Central Africa
20
Latin America and the Carribbean
19
East and Southern Africa
18
Brazil
18
Africa
17
Guinea
16
Congo, Democratic Republic of
15
Russia
14
Ukraine
13
Ghana
13
Zambia
13
Rwanda
12
Bangladesh
12
Eastern Europe
12
Nepal
10
Malawi
10
Tanzania
10
Germany
10
South Sudan
10
Syria
9
Zimbabwe
9
Philippines
9
Mozambique
9
Cambodia
9
South–East Asia Region
9
Myanmar / Burma
9
Middle East and North Africa
8
Namibia
7
Senegal
6
Asia
6
Burkina Faso
5
Eastern Europe and Central Asia
5
Vietnam
5
Lesotho
4
Haiti
4
Central African Republic
4
Botswana
4
Indonesia
4
Thailand
3
China
3
Chile
3
Cameroon
3
Laos
3
USA
3
Paraguay
3
United Kingdom
3
Lebanon
3
Yemen
3
Angola
3
Turkey
2
Peru
2
Guinea-Bissau
2
Venezuela
2
Jordan
2
Spain
2
Côte d’Ivoire / Ivory Coast
2
Argentina
2
Papua New Guinea
2
Sudan
2
Chad
2
Madagascar
2
Tajikistan
1
Mexico
1
El Salvador
1
Benin
1
Gambia
1
Iran
1
Albania
1
Kyrgyzstan
1
Niger
1
Malaysia
1
Morocco
1
Bulgaria
1
Italy
1
Western Pacific Region
1
Gabon
1
Japan
1
Denmark
1
France
1
Tunisia
1
Portugal
1
Southern Africa
1
Moldova
1
Honduras
1
Mali
1
Iraq
1
Somalia
1
Ecuador
1
Eswatini/ Swaziland
1
Pakistan
1
Authors & Publishers
Publication Years
Category
Countries
429
Clinical Guidelines
175
Women & Child Health
79
Public Health
75
Key Resources
41
Pharmacy & Technologies
21
Capacity Building
8
Toolboxes
COVID-19
319
HIV
112
TB
112
Ebola & Marburg
85
NTDs
73
AMR
61
Rapid Response
60
Pharmacy
35
Mental Health
26
Health Financing Toolbox
23
Global Health Education
22
Planetary Health
21
Conflict
21
Refugee
19
Caregiver
15
NCDs
14
Cholera
13
Polio
13
Zika
12
Natural Hazards
5
Disability
5
Specific Hazards
4
Malaria
2
Herd immunity by mass vaccination offers the potential to substantially limit the continuing spread of COVID-19, but high levels of vaccine hesitancy threaten this goal. In a cross-country analysis of vaccine hesitant respondents across Latin America in January 2021, we experimentally tested how fiv...
orientations provisoires, première publication: 10 février 2021, mise à jour : 21 avril 2021, dernière mise à jour : 30 juillet 2021
9 September 2020
In a snapshot, fair allocation of vaccines will occur in the following way:
An initial proportional allocation of doses to countries until all countries reach enough quantities to cover 20% of their population
This document is also available in Arabic | Chinese | French | R...
The Lancet Volume 5, Issue 10100972October 2024 Chagas Disease Serie 3
Principles and Target Product Criteria. Roadmap January 12, 2015
Development of one or more vaccines for Neisseria gonorrhoeae is an important objective for sexual and reproductive health worldwide, and for the fight against antimicrobial resistance.
WHO preferred product characteristics (PPCs) provide strategic guidance as to WHO’s preferences for new vacci...
“Guide to facilitate the implementation of the WHO/UNICEF “Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines” for Africa
t contains action-oriented lists of critical topics to address and checklists tailored to the context of African Union Member States.
...
Taking the whole of Africa approach to fighting the COVID-19 pandemic has and will continue to require coordinated efforts from multiple stakeholders from across the continent. Africa CDC would like to acknowledge the deep partnership and continued support of AUDA-NEPAD, AVAREF, WHO AFRO, the Bill a...
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc...
nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
An example of integration of research into epidemic response.
orientations provisoires, première publication : 8 janvier 2021, mise à jour : 15 juin 2021, mise à jour : 19 novembre 2021, mise à jour : 21 janvier 2022
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Th...
AstraZeneca-SKBio in South Korea and Serum Institute of India
The position papers are intended for use by national public health officials and managers of immunization programmes. They may also be of interest to international funding agencies, vaccine advisory groups, vaccine manufacturers, health professionals, researchers, the scientific media and the genera...
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir...
